← Back to headlines
Merck's Cholesterol Drug Meets Main Goal in Head-to-Head Trial
A late-stage trial of a new Merck drug demonstrated a reduction in bad cholesterol by up to 64.6%, meeting its main goal in a head-to-head trial.
30 Mar, 16:09 — 30 Mar, 16:09
Sources
Showing 1 of 2 sources
Coverage Timeline
First report: Yahoo · 30 Mar, 16:09|Full coverage: 2 · 4h|Window: 4h
Left-leaningCenterRight-leaning
